Baltimore plays a losing economic development hand

Economic development officials in Baltimore are fretting that they're one step behind the pace being set in Montgomery County, where low-cost lab space along with offers of small loans and grants have been luring away emerging drug developers. In the case of Amulet Pharmaceuticals, a spinoff of Johns Hopkins, a $25,000 loan and some free PR proved too much to ignore.

It's a big issue for Baltimore, which has two new bioparks to fill. One particularly thorny issue, according to the Baltimore Business Journal, is getting the city of Baltimore to work as a team with the county. Another key will be in coming up with competitive lease rates for developers in need of lab space.

- read the article in the Baltimore Business Journal

Related Article:
Top Five Regions Targeting Biotech Companies - 2008

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.